Insider · CIK 0001269971
Andrew N Liveris
director
Files at IBM (INTERNATIONAL BUSINESS MACHINES CORP), LCID (Lucid Group, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | IBM INTERNATIONAL BUSINESS MACHINES CORP | AGrant or award Promised Fee Sharederivative | +444 | $219.93 | $98k | 45,262 | 12 d ago |
| Dec 31, 2025 | IBM INTERNATIONAL BUSINESS MACHINES CORP | AGrant or award Promised Fee Sharederivative | +330 | $296.21 | $98k | 43,186 | Jan 2, 2026 |
| Sep 30, 2025 | IBM INTERNATIONAL BUSINESS MACHINES CORP | AGrant or award Promised Fee Sharederivative | +346 | $282.16 | $98k | 42,628 | Oct 1, 2025 |
| Jun 30, 2025 | IBM INTERNATIONAL BUSINESS MACHINES CORP | AGrant or award Promised Fee Sharederivative | +331 | $294.78 | $98k | 42,008 | Jul 1, 2025 |
| Jun 5, 2025 | LCID Lucid Group, Inc. | AGrant or award Class A Common Stock | +108,713 | $0.00 | $0 | 794,099 | Jun 9, 2025 |
| Jun 5, 2025 | LCID Lucid Group, Inc. | AGrant or award Class A Common Stock | +4,831 | $0.00 | $0 | 798,930 | Jun 9, 2025 |
| Mar 31, 2025 | IBM INTERNATIONAL BUSINESS MACHINES CORP | AGrant or award Promised Fee Sharederivative | +393 | $248.66 | $98k | 41,425 | Apr 1, 2025 |
| Dec 31, 2024 | IBM INTERNATIONAL BUSINESS MACHINES CORP | AGrant or award Promised Fee Sharederivative | +421 | $219.83 | $93k | 40,768 | Jan 2, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.